14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 MDGL stock ended at $229.84. This is 6.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.88% from a day low at $221.25 to a day high of $234.25.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Nov 02, 2023 $137.72 $140.44 $136.16 $137.40 374 831
Nov 01, 2023 $132.17 $136.74 $130.78 $136.49 388 871
Oct 31, 2023 $125.57 $132.95 $125.57 $131.38 408 933
Oct 30, 2023 $120.65 $128.84 $120.65 $126.15 378 683
Oct 27, 2023 $124.77 $124.87 $119.76 $120.40 359 552
Oct 26, 2023 $123.08 $126.44 $121.17 $124.91 289 963
Oct 25, 2023 $124.15 $125.61 $121.07 $123.39 416 245
Oct 24, 2023 $128.09 $129.82 $125.79 $126.42 410 411
Oct 23, 2023 $129.86 $131.85 $125.61 $125.92 467 939
Oct 20, 2023 $130.76 $133.70 $129.12 $131.54 271 468
Oct 19, 2023 $136.04 $136.04 $129.50 $130.32 382 549
Oct 18, 2023 $140.17 $140.17 $133.72 $136.10 472 278
Oct 17, 2023 $140.67 $142.63 $139.27 $140.52 263 071
Oct 16, 2023 $139.82 $142.10 $138.45 $141.02 452 643
Oct 13, 2023 $136.32 $141.10 $133.85 $140.37 391 804
Oct 12, 2023 $138.02 $138.58 $130.62 $135.75 792 063
Oct 11, 2023 $147.23 $148.15 $138.01 $138.92 565 242
Oct 10, 2023 $144.19 $151.96 $140.65 $149.41 811 600
Oct 09, 2023 $140.08 $142.65 $137.28 $140.02 300 479
Oct 06, 2023 $137.11 $143.01 $135.74 $140.88 316 114
Oct 05, 2023 $136.18 $142.78 $133.66 $140.49 353 965
Oct 04, 2023 $141.00 $141.00 $133.00 $135.76 588 020
Oct 03, 2023 $140.00 $141.40 $137.00 $140.79 597 380
Oct 02, 2023 $146.00 $146.04 $139.33 $143.36 803 741
Sep 29, 2023 $161.00 $163.66 $144.50 $146.04 1 838 463
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT